Table 1.
Selected series of vestibular schwannoma treated by stereotactic radiosurgery (SRS), fractionated stereotactic radiotherapy (FSRT) and protons.
| Author | Year | Institution | N. of pts | Median follow-up (months) | Median dose | Mean/Median volume (cc) | Local control | Hearing preservation | Toxicity |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| VII c.n. | V c.n. | Others | |||||||||
| SRS | |||||||||||
| Breivik14 | 2013 | Bergen, Norway | 113 | 55 | 12 Gy | 3.9 | 94% | 36% | 12% | NA | 0% |
| Hasegawa13 | 2013 | Komaki, Japan | 440 | 12.5 y | 12.8 Gy | 2.8 | 93% 5 y 92% 10 y |
43% 5 y 34% 8 y |
2.2% | 0.5% | 0.2–0.7% |
| Boari12 | 2014 | San Raffaele, Italy | 379 | 75.7 | 13 Gy | 1.2 | 97.1% | 49% | 1.1% | 1.8% | 3.2% disequilibrium 3.2% tinnitus 1.8% headache 5.3% hydrocephalus |
| FSRT (conventional fractionation) | |||||||||||
| Champ19 | 2013 | Philadelphia, USA | 154 | 35 | 46.8 Gy, 26 fxs | 2.41/0.09 | 99% 3 y 93% 5 y |
64% 3 y 54% 5 y |
1.9% | 1.9% | 4.5% imbalance 1.9% hydrocephalus |
| Woolf17 | 2013 | London, UK | 93 | 5.7 y | 52.5 Gy, 25 fxs | 19.6 mm (mean diameter) |
93% 5 y 92% 10 y |
93% | 1% | 1% | NA |
| Litre18 | 2013 | Reims, France | 155 | 60 | 50.4 Gy, 28 fxs | 2.45 | 99.3% 3 y 97.5% 5 y 95.2% >7y |
54% | 2.5% | 3.2% | 2.5% hydrocephalus 2.1% tinnitus |
| FSRT (hypofractionation) | |||||||||||
| Hansasuta20 | 2011 | Standford, USA | 383 | 3.6 y | 18 Gy, 3 fxs | 1.1 | 97% 99% 3 y 96% 5 y |
All, 76% T≥3cc 59% T < 3cc 80% |
0.2% | 1% | 1% hydrocephalus |
| Tsai21 | 2013 | Taipei, Taiwan | 117 | 61.1 | 18 Gy, 3 fxs | 4.7 | 99.1% | 81.5% | NA | NA | NA |
| Vivas22 | 2014 | Pittsburgh, USA | 73 | 40 | 18 Gy, 3 fxs | 0.81 | 83% | 53.5% | NA | NA | NA |
| Vernimmen23* | 2009 | Tygerberg, South Africa | 51 | 60 | 26 CGyE, 3 fxs | 3.45 | 98% | 42% | 8.3% | 8.3% | NA |
SRS, radiosurgery (marginal dose); FSRT, fractionated stereotactic radiotherapy; y, years; NA, not available
*Proton radiotherapy